MX2007003624A - Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. - Google Patents

Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.

Info

Publication number
MX2007003624A
MX2007003624A MX2007003624A MX2007003624A MX2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A MX 2007003624 A MX2007003624 A MX 2007003624A
Authority
MX
Mexico
Prior art keywords
peptides
pharmaceutical compositions
hsp60
apl
mechanisms
Prior art date
Application number
MX2007003624A
Other languages
English (en)
Inventor
Horta Maria Del Carmen Dominguez
Palomares Gabriel Ramon Padron
Marin Nelia Lopez
Perez Norailys Lorenzo
Betancourt Ariana Barbera
Garcia Ariadna Hernandez
Cordova Vivian Morera
Diaz Carelia Cosme
Garcia Nelson J Merino
Bonachea Ariel Vazquez
Alba Jose Suarez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of MX2007003624A publication Critical patent/MX2007003624A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptidos de la proteina humana de estres termico de 60 kDa que constituyen epitopes para celulas T, asi como peptidos derivados de ellos, los cuales estan modificados en los sitios de contacto con la molecula MHC,utiles para inducir mecanismos de tolerancia periferica, en particular mecanismos inductores de anergia o mediados por clones de celulas T regulatorias en pacientes con Artritis Reumatoide; la invencion tambien refiere composiciones farmaceuticas que comprenden tales peptidos para tratamiento de la Artritis Reumatoide.
MX2007003624A 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. MX2007003624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040207A CU23504A1 (es) 2004-09-24 2004-09-24 Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
PCT/CU2005/000008 WO2006032216A2 (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas

Publications (1)

Publication Number Publication Date
MX2007003624A true MX2007003624A (es) 2007-06-13

Family

ID=40273413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003624A MX2007003624A (es) 2004-09-24 2005-09-22 Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.

Country Status (17)

Country Link
US (2) US8383771B2 (es)
EP (2) EP1803732B1 (es)
JP (1) JP4755649B2 (es)
KR (2) KR101054332B1 (es)
CN (2) CN101065398B (es)
AR (2) AR051928A1 (es)
AT (1) ATE546462T1 (es)
AU (2) AU2005287757B2 (es)
BR (2) BR122018077204B8 (es)
CA (2) CA2581110C (es)
CU (1) CU23504A1 (es)
DK (2) DK1803732T3 (es)
ES (2) ES2386498T3 (es)
MX (1) MX2007003624A (es)
RU (1) RU2361877C2 (es)
WO (1) WO2006032216A2 (es)
ZA (1) ZA200702938B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423222B2 (en) * 2007-01-30 2020-07-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
RU2596925C2 (ru) * 2009-09-06 2016-09-10 Протаб Лтд. Гуманизированные антитела, специфические для пептида-6, полученного из hsp65, способы их использования
WO2011059758A2 (en) * 2009-10-28 2011-05-19 Argentis Pharmaceuticals, Llc Apls for treating arthritis
CU24508B1 (es) 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
KR102333645B1 (ko) 2021-07-27 2021-12-02 (주)문화전기 각도조절이 용이한 엘이디조명시스템
CN117883547A (zh) * 2021-07-30 2024-04-16 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5773570A (en) 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
GB9419553D0 (en) 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
US6180103B1 (en) 1994-12-21 2001-01-30 Yeda Research And Development Co., Ltd. Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9519737D0 (en) * 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
GB9911772D0 (en) 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
US20020169302A1 (en) * 1999-08-23 2002-11-14 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
NZ519348A (en) * 1999-12-15 2006-04-28 Develogen Israel Ltd Fragments and antagonists of heat shock protein 60
WO2002057795A2 (en) 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis

Also Published As

Publication number Publication date
KR101054332B1 (ko) 2011-08-04
BRPI0515893B1 (pt) 2020-09-15
BR122018077204B1 (pt) 2020-01-28
KR20070073787A (ko) 2007-07-10
KR101035283B1 (ko) 2011-05-18
CA2581110C (en) 2013-04-02
DK1803732T3 (da) 2012-05-29
BR122018077204B8 (pt) 2021-07-27
AU2005287757A1 (en) 2006-03-30
EP2371847A1 (en) 2011-10-05
US20100144642A1 (en) 2010-06-10
AU2005287757B2 (en) 2010-07-29
AR074924A2 (es) 2011-02-23
BRPI0515893A8 (pt) 2019-01-02
ES2445707T3 (es) 2014-03-04
US8383771B2 (en) 2013-02-26
AR051928A1 (es) 2007-02-21
AU2010219312A1 (en) 2010-09-23
CN101935345B (zh) 2013-12-11
EP1803732A2 (en) 2007-07-04
CA2797769A1 (en) 2006-03-30
JP4755649B2 (ja) 2011-08-24
BRPI0515893A (pt) 2008-08-12
CN101065398B (zh) 2012-12-19
AU2010219312B2 (en) 2011-10-06
RU2007115411A (ru) 2008-10-27
DK2371847T3 (da) 2014-02-03
RU2361877C2 (ru) 2009-07-20
CN101065398A (zh) 2007-10-31
WO2006032216A3 (es) 2007-05-18
ES2386498T3 (es) 2012-08-22
ATE546462T1 (de) 2012-03-15
CU23504A1 (es) 2010-04-13
US8324164B2 (en) 2012-12-04
ZA200702938B (en) 2008-08-27
BRPI0515893B8 (pt) 2021-05-25
JP2008514553A (ja) 2008-05-08
KR20100028645A (ko) 2010-03-12
EP1803732B1 (en) 2012-02-22
US20090171069A1 (en) 2009-07-02
EP2371847B1 (en) 2013-11-20
WO2006032216A2 (es) 2006-03-30
CN101935345A (zh) 2011-01-05
CA2581110A1 (en) 2006-03-30
CA2797769C (en) 2015-09-15

Similar Documents

Publication Publication Date Title
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
HK1109636A1 (en) Human antibodies and proteins
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
EA201000424A1 (ru) Антитела к il-23
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
WO2015095301A3 (en) Cytotoxic peptides and conjugates thereof
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
HK1101131A1 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof
WO2009087467A3 (en) Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
JOP20190101A1 (ar) أنظمة علاج
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
Lund Selection of Proteins for Human MHC Class Ⅱ Presentation

Legal Events

Date Code Title Description
FG Grant or registration